Biocytogen provides comprehensive, one-stop solutions for next-generation drug development, supporting the global biomedical community from target identification to IND application. Leveraging proprietary gene-editing technology and the innovative RenMice® platforms, Biocytogen offers fully human antibody discovery, featuring a library of over 400,000 sequences targeting nearly 1,000 antigens for global partnerships. Our technical teams also deliver an extensive portfolio of products and services, including drug-targeted humanized models, comprehensive preclinical pharmacology services, and custom gene-editing solutions. Biocytogen collaborates with all top 10 and 70% of the top 50 pharmaceutical companies, as well as numerous biotech start-ups worldwide, driving innovation in drug discovery and development.
Site |
Badges |
|
Biocytogen Boston Corporation
300 3rd Ave
Waltham, MA, 02451
United States
|
|
|
Eli Lilly @ CRL CRADL
100 Binney St 5th Floor
Cambridge, MA, 02142
United States
|
|
|
Biocytogen Boston Corp.
300 3rd Ave
Waltham, MA, 02451
United States
|
|
|
BIOCYTOGEN BEIJING; Biocytogen Pharmaceuticals (Beijing) Co., Ltd.,
No. 12, Baoshen South Street
Daxing, Beijing, 102609
China
|
|
|
BIOCYTOGEN HAIMEN Jiangsu Co., Ltd.,
Building #12
Linjiang New District, Haimen Jiangsu Province, 226100
China
|
|